PARP inhibitors offer great potential to improve outcomes for patients with ovarian cancer, and evidence will hopefully support their use in the first-line management of these patients, said Susana M. Campos, MD, a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School, during her talk at the 35th annual CFS<sup>®</sup> meeting.
Susana M. Campos, MD
Susana M. Campos, MD
PARP inhibitors offer great potential to improve outcomes for patients with ovarian cancer, and evidence will hopefully support their use in the first-line management of these patients, said Susana M. Campos, MD, a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School, during her talk at the 35th annual CFS®meeting.
“It’s important that we start to use these drugs more and more and bring them sooner into the management of the individual,” said Campos, who reviewed trial data and approvals for several PARP inhibitors and looked at the potential for advancing the use of these agents.
Various PARP inhibitors, which interfere with tumor cell ability to make DNA strand repairs, have been approved by the FDA for use following platinum therapy and for maintenance in the ovarian setting. Those include olaparib (Lynparza), for germlineBRCAmutations (gBRCAm) following 3 prior lines of therapy; rucaparib (Rubraca), for gBRCAm and somaticBRCAm following 2 prior lines; and niraparib (Zejula) and olaparib for post-platinum maintenance.
Several trials of these agents are important for the light they shed on PARP capabilities, Campos said. Those include NOVA, SOLO-2, STUDY 19, and ARIEL-3.
The NOVA trial applied niraparib in platinum-sensitive, recurrent, high-grade, serous carcinoma, in patients previously treated with at least 4 cycles of a platinum-containing agent who had shown response, partial or complete. Treatment dosage was 300 mg daily. In the gBRCAm cohort, the median progression-free survival (PFS) for niraparib was 21 months versus 5.5 months on placebo; and in the non-gBRCAm homologous repair defect (HRD)-positive cohort the median PFS was 12.9 and 3.8 months, respectively. In the overall non-gBRCAm group, the median PFS was 9.3 months on niraparib versus 3.9 for placebo. “Niraparib improved PFS across all 3 groupsgermline and nongermline,” Campos noted.
The SOLO-2 study was unique in that it accruedBRCA1andBRCA2mutation carriers only, she said. Patients had at least 2 prior lines of platinum therapy and had demonstrated sensitivity to platinum. Dosage was 300 mg twice daily. The olaparib group (n = 196) had a median PFS of 19.1 months versus 5.5 months for those on placebo (HR, 0.30; 95% CI, 0.22-0.41;P<.0001).
STUDY 19 enrolled patients with platinum-sensitive, high-grade serous ovarian cancer and ≥2 previous platinum regimens. Of 265 recruited, 22% wereBRCApositive and 14% wereBRCAnegative. Olaparib dosage was 400 mg orally, twice daily. Treatment was until disease progression. In the primary analysis, median PFS was 8.4 months for olaparib and 4.8 months on placebo (HR, 0.35; 95% CI, 0.25-0.49;P<.001). Campos noted that what was particularly significant about this study was that it accepted all comers, whether they wereBRCAcarriers or not.
The ARIEL3 study was a phase III randomized trial of rucaparib versus placebo in patients with ovarian cancer who had responded to platinum therapy. In the BRCAm subgroup, median PFS was 16.6 months for rucaparib and 5.4 months on placebo; for patients in the HRD BRCA germline or somatic group, the median PFS was 13.6 versus 5.4 months; and in a third group that included germline or somaticBRCAm plusBRCAwild-type, the median PFS was 10.8 months for patients on rucaparib versus 5.4 months for those on placebo.
Although the trials produced striking efficacy data, “It’s also important to balance [treatment decisions] with knowledge of toxicity, and in truth all PARP inhibitors share some common toxicities in terms of gastrointestinal toxicities as well as hematological adverse events [AEs],” Campos said. Common AEs included anemia, neutropenia, and thrombocytopenia. “Thrombocytopenia was seen a bit frequently in the NOVA trial very early on, but it was clearly attenuated with a dose reduction, so that is quite important.”
“There are other toxicities that can be unique to 1 or 2 particular agents, and as you tailor these drugs to your patients, knowing these toxicities is extremely important.” Metabolic effects and drug-to-drug interactions are also important to understand, she noted.
“We want these drugs in the upfront setting,” and the question is whether past and ongoing trial activity will provide the necessary evidence for doing so, Campos said. In addition, there are other riddles that need to be solved, such as the workings of mechanisms of resistance to PARP inhibitors and whether PARP inhibitors can be used after PARP inhibitors. “The elephant in the room is how can testing strategies forBRCAm or non-BRCAm ovarian cancer be used to personalize treatment strategies?” she said.